Titrating a GLP-1 agonist in CKD

Clinical stem

A 58-year-old with CKD stage 3b (eGFR 34) and type 2 diabetes, on furosemide, lisinopril, and empagliflozin, is starting semaglutide for weight and glycemic control.

The trap

Assuming the weekly agent needs renal dose reduction — it does not — while missing the real risk: nausea, vomiting, or diarrhea causing volume depletion on top of a diuretic, ACE inhibitor, and SGLT2 inhibitor, precipitating prerenal AKI.

Diagnostic reasoning

GLP-1 and dual agonists are not renally cleared and need no dose adjustment for GFR. The renal risk is indirect: GI losses lead to hypovolemia and prerenal AKI, amplified by diuretics, ACE inhibitors/ARBs, NSAIDs, and SGLT2 inhibitors. Titrate slowly for tolerability.

Safety pearl

Set a sick-day plan in advance: hold the diuretic, ACE inhibitor/ARB, and SGLT2 inhibitor (and avoid NSAIDs) during vomiting or diarrhea; keep fluids up; recheck creatinine and electrolytes after initiation and each dose step, watching for hypokalemia and metabolic alkalosis from vomiting.

What not to overclaim

FLOW proves a kidney-outcome benefit for semaglutide in type 2 diabetes with CKD; do not extrapolate hard-outcome renoprotection to every agent or to non-diabetic CKD. On sick days it is the companion drugs that are held, not the weekly injection.